⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96226 | 0.76 | — | — | |
| SCHEMBL1834958 | 0.76 | — | — | |
| SCHEMBL4442166 | 0.74 | ERN1 (0.39) | — | |
| SCHEMBL27970908 | 0.73 | — | — | |
| SCHEMBL154875 | 0.73 | — | — | |
| SCHEMBL17158709 | 0.72 | EIF2AK2 (0.47) | — | |
| SCHEMBL17158712 | 0.72 | EIF2AK2 (0.47) | — | |
| SCHEMBL19494594 | 0.72 | ERN1 (0.34) | — | |
| SCHEMBL13160445 | 0.70 | ALDH1A1 (0.58) | — | |
| SCHEMBL1021333 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638438-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | Xinthera, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240317733-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-09-26 | — | — | US | disclosed |
| US-20240279214-A1 | ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2024138042-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138042-A1 | ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF | XINTHERA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-17 | — | — | US | disclosed |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| WO-2015156417-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291577-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| WO-2014094357-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014094357-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |